As of Oct 20
| +0.47 / +5.35%|
The 4 analysts offering 12-month price forecasts for Redhill Biopharma Ltd have a median target of 25.50, with a high estimate of 36.00 and a low estimate of 19.00. The median estimate represents a +175.68% increase from the last price of 9.25.
The current consensus among 4 polled investment analysts is to Buy stock in Redhill Biopharma Ltd. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.